CytoDyn(OTC) CYDY

CytoDyn develops experimental medicines for serious diseases like HIV and cancer. Its main drug candidate, leronlimab, aims to help patients with limited treatment options. The company focuses on therapies that target the immune system in new ways.

Lab Bench to Bedside: CytoDyn’s Main Offerings

• Leronlimab (PRO 140): An antibody drug in clinical trials for HIV, cancer, and liver disease. Represents 0% of revenue as of August 2025.
• HIV Treatment: Leronlimab is being tested as a new way to block HIV from entering cells. No commercial sales yet.
• Oncology Applications: Trials underway for hard-to-treat cancers, including metastatic triple-negative breast cancer and colorectal cancer. No revenue generated.
• Liver Disease (NASH): Researching leronlimab for non-alcoholic steatohepatitis, a liver condition with few treatments. No sales to date.
• COVID-19 Research: Investigating leronlimab’s potential in treating COVID-19 complications. No product sales reported.

Growth Spurts and Stumbles: CytoDyn’s Expansion Moves

• Launched Phase II trial for colorectal cancer in 2025, expanding into solid tumor research.
• Started Phase 1b/2 trial for metastatic triple-negative breast cancer in 2025.
• Developing a long-acting version of leronlimab to broaden future applications.
• Pursuing strategic partnerships and licensing deals to fund research, with no major acquisitions reported.
• Focused on U.S. clinical development; no global market entries as of August 2025.

What Makes CytoDyn Stand Out (or Not)

CytoDyn operates with a small team and a single drug focus. Its approach targets the CCR5 receptor, a protein linked to immune system activity. The company’s strategy relies on clinical trial progress and external funding, not commercial sales.

Five Things You Need to Know

• Revenue was $0 in Q1 2026, unchanged from Q1 2025 and Q1 2024.
• Operating loss was $5 million in Q1 2026, down 120.4% from Q1 2025.
• Cash and equivalents were $9.3 million as of August 31, 2025.
• Total liabilities reached $113 million, with a stockholders’ deficit of $99.5 million in Q1 2026.
• Accumulated deficit was $893.3 million as of August 31, 2025.

Bottom Line

CytoDyn remains a clinical-stage company with no product sales and ongoing financial challenges. Its future depends on successful drug development and securing new funding sources.